Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22997177 | 1.00 | PDPK1 (0.52) | PDPK1HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL7500388 | 1.00 | PDPK1 (0.52) | PDPK1HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL29858433 | 1.00 | PDPK1 (0.52) | PDPK1HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL5017486 | 0.84 | ITGB2 (0.46) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL6431777 | 0.84 | ITGB2 (0.46) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL18215053 | 0.81 | ITGB2 (0.43) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL12162969 | 0.81 | ITGB2 (0.43) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL2790683 | 0.81 | ITGB2 (0.43) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL5019354 | 0.80 | HTR2A (0.50) | HTR2AITGB2ICAM1ITGAL | |
| SCHEMBL31595597 | 0.80 | HTR2A (0.50) | HTR2AITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023107356-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023102747-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230139282-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139282-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1192146-A1 | CHROMAN DERIVATIVES RESISTING NEUROLOGICAL DISORDERS | AstraZeneca UK Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000078742-A1 | CHROMAN DERIVATIVES AGAINST NEUROLOGICAL DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139282-A1 | ANTIMALARIAL AGENTS | G6PD, MTX1, OAT | PDPK1 2929/4885HTR2A 4669/4885ITGB2 2103/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | PDPK1 3375/4885HTR2A 635/4885ITGB2 591/4885 |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | CTSL, PRCP, CPB1 | PDPK1 1711/4885HTR2A 4790/4885ITGB2 1989/4885 |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | PDPK1 313/4885HTR2A 1772/4885ITGB2 4315/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | PDPK1 2678/4885HTR2A 3135/4885ITGB2 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.